Pure Extracts Technologies (PULL.C) set their milestone timetable for their study on both the formulation and manufacturing of psilocybin-based treatments today, according to a press release.

The study’s focus will be on dosage testing for formulating, manufacturing and bioavailability that could be used in any future clinical trials by both Pure and their pharmaceutical customers. The company has put together clinical batch manufacturing, packaging and labelling into the study, in addition to conformity testing and stability testing. The study will conform to both Canadian Good Manufacturing Practice (GMP) and Good Clinical Practice Standards (GCP).

“We are excited about the R&D progress we are going to make with TIPT over the next 6 – 8 months while waiting to receive our Dealer’s License from Health Canada. We will be well prepared for our move into the controlled substances world of psychedelics and will have advanced knowledge regarding psilocybin and its associated novel delivery mechanisms,” said Ben Niklaevsky, CEO of Pure Extracts.

The key milestones in the 250-day timeline include:

  • Sourcing and procurement of medicinal ingredients, excipients & packaging materials
  • Raw Material Testing
  • Formulation and Manufacturing Process Development, Stability Testing
  • Clinical Batch Manufacturing
  • Quality Control Release Testing
  • Shipping of Clinical Batches to CRO

The company is intending on producing these formulations in an oral tablet, capsule and nasal gel format, which will be used as an investigational product and overseen at the Toronto Institute of Pharmaceutical Technology by Dr. Alexander MacGregor, who has been doing the science duties for the company.

Source: stockwatch.com

PULL is up 8.1% and now trading at $0.67

—Joseph Morton

Full disclosure: Pure Extracts Technologies is an equity.guru marketing client.

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
Tags:
Cannabis
Pharmaceuticals
Bioavailability
Canadian Good Manufacturing Practice
clinical trial
Good Clinical Practice Standards
Psilocybin
psilocybin studies
psilocybin study
PULL.C
Pure Extracts
Pure Extracts Technologies
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments